Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma
Open Access
- 8 January 2020
- journal article
- research article
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 6 (2), 113-123
- https://doi.org/10.1002/cjp2.156
Abstract
The expression of p16/CDKN2A, the second most commonly inactivated tumour suppressor gene in cancer, is lost in the majority of chordomas. However, the mechanism(s) leading to its inactivation and contribution to disease progression have only been partially addressed using small patient cohorts. We studied 384 chordoma samples from 320 patients by immunohistochemistry and found that p16 protein was lost in 53% of chordomas and was heterogeneously expressed in these tumours. To determine if CDKN2A copy number loss could explain the absence of p16 protein expression we performed fluorescence in situ hybridisation (FISH) for CDKN2A on consecutive tissue sections. CDKN2A copy number status was altered in 168 of 274 (61%) of samples and copy number loss was the most frequent alteration acquired during clinical disease progression. CDKN2A homozygous deletion was always associated with p16 protein loss but only accounted for 33% of the p16‐negative cases. The remaining immunonegative cases were associated with disomy (27%), monosomy (12%), heterozygous loss (20%) and copy number gain (7%) of CDKN2A, supporting the hypothesis that loss of protein expression might be achieved via epigenetic or post‐transcriptional regulatory mechanisms. We identified that mRNA levels were comparable in tumours with and without p16 protein expression, but other events including DNA promoter hypermethylation, copy number neutral loss of heterozygosity and expression of candidate microRNAs previously implicated in the regulation of CDKN2A expression were not identified to explain the protein loss. The data argue that p16 loss in chordoma is commonly caused by a post‐transcriptional regulatory mechanism that is yet to be defined.Keywords
Funding Information
- National Institute for Health Research
- Pathological Society of Great Britain and Ireland (Reference No: TSGS 2016 10 02, TSGS 2016 10 02)
- Cancer Research UK (18387)
- UCLH Biomedical Research Centre
- Chordoma Foundation
This publication has 35 references indexed in Scilit:
- EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screenThe Journal of Pathology, 2016
- Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosisActa Neuropathologica, 2016
- Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle PathwayCancer Research, 2015
- Long Noncoding RNA, Polycomb, and the Ghosts Haunting INK4b-ARF-INK4a ExpressionCancer Research, 2011
- Human Glioma Growth Is Controlled by MicroRNA-10bCancer Research, 2011
- Recurrent Chromosomal Copy Number Alterations in Sporadic ChordomasPLOS ONE, 2011
- A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroupsBlood, 2009
- Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisationBritish Journal of Cancer, 2007
- Loss of p16Ink4a confers susceptibility to metastatic melanoma in miceNature, 2001
- Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesisNature, 2001